SEARCH

SEARCH BY CITATION

References

  • Beyer, M., Kochanek, M., Darabi, K., Popov, A., Jensen, M., Endl, E., Knolle, P.A., Thomas, R.K., Von Bergwelt-Baildon, M., Debey, S., Hallek, M. & Schultze, J.L. (2005) Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood, 106, 20182025.
  • Chen, J., Schmitt, A., Bunjes, D., Chen, B. & Schmitt, M. (2007a) The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation. International Journal of Oncology, 30, 11191127.
  • Chen, J., Schmitt, A., Chen, B., Rojewski, M., Ringhoffer, M., Von Harsdorf, S., Greiner, J., Guillaume, P., Döhner, H., Bunjes, D. & Schmitt, M. (2007b) Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. Cancer Immunology, Immunotherapy, 56, 849861.
  • Chen, J., Schmitt, A., Giannopoulos, K., Chen, B., Rojewski, M., Döhner, H., Bunjes, D. & Schmitt, M. (2007c) Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. International Journal of Oncology, 31, 11331139.
  • Cortes, J., Rousselot, P., Kim, D.W., Ritchi, E., Hamerschlak, N., Coutre, S., Hochhaus, A., Guilhot, F., Saglio, G., Apperley, J., Ottmann, O., Shah, N., Erben, P., Branford, S., Agarwal, P., Gollerkeri, A. & Baccarani, M. (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 109, 32073213.
  • Cwynarski, K., Laylor, R., Macchiarulo, E., Goldman, J., Lombardi, G., Melo, J.V. & Dazzi, F. (2004) Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia, 18, 13321339.
  • Edinger, M., Hoffmann, P., Ermann, J., Drago, K., Fathman, C.G., Strober, S. & Negrin, R.S. (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nature Medicine, 9, 11441150.
  • Fei, F., Yu, Y., Schmitt, A., Rojewski, M.T., Chen, B.A., Ringhoffer, M., Harsdorf, S., Greiner, J., Goetz, M., Guillaume, P., Doehner, H., Bunjes, D. & Schmitt, M. (2008) Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia-antigens. Experimental Hematology, 36, 12971308.
  • Fontenot, J.D., Gavi, M.A. & Rudensky, A.Y. (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature Immunology, 4, 330336.
  • Guilhot, F., Apperley, J., Kim, D.W., Bullorsky, E.O., Baccarani, M., Roboz, G.J., Amadori, S., De Souza, C.A., Lipton, J.H., Hochhaus, A., Heim, D., Larson, R.A., Branford, S., Muller, M.C., Agarwal, P., Gollerkeri, A. & Talpaz, M. (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 109, 41434150.
  • Von Herrath, M.G. & Harrison, L.C. (2003) Antigen-induced regulatory T cells in autoimmunity. Nature reviews. Immunology, 3, 223232.
  • Hipp, M.M., Hilf, N., Walter, S., Werth, D., Brauer, K.M., Radsak, M.P., Weinschenk, T., Singh-Jasuja, H. & Brossart, P. (2008) Sorafenib but not sunitinib affects function of dendritic cells and induction of primary immune responses. Blood, 111, 56105620.
  • Hochhaus, A., Kantarjian, H.M., Baccarani, M., Lipton, J.H., Apperley, J.F., Druker, B.J., Facon, T., Goldberg, S.L., Cervantes, F., Niederwieser, D., Silver, R.T., Stone, R.M., Hughes, T.P., Muller, M.C., Ezzeddine, R., Countouriotis, A.M. & Shah, N.P. (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 109, 23032309.
  • Hoffmann, P., Eder, R., Kunz-Schughart, L.A., Andreesen, R. & Edinger, M. (2004) Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood, 104, 895903.
  • Johnson, F.M., Saigal, B., Talpaz, M. & Donato, N.J. (2005) Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clinical Cancer Research, 11, 69246932.
  • Kantarjian, H.M., Talpaz, M., Giles, F., O’Brien, S. & Cortes, J. (2006) New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Annals of Internal Medicine, 145, 913923.
  • Li, L., Godfrey, W.R., Porter, S.B., Ge, Y., June, C.H., Blazar, B.R. & Boussiotis, V.A. (2005) CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood, 106, 30683073.
  • Lombardo, L.J., Lee, F.Y., Chen, P., Norris, D., Barrish, J.C., Behnia, K., Castaneda, S., Cornelius, L.A., Das, J., Doweyko, A.M., Fairchild, C., Hunt, J.T., Inigo, I., Johnston, K., Kamath, A., Kan, D., Klei, H., Marathe, P., Pang, S., Peterson, R., Pitt, S., Schieven, G.L., Schmidt, R.J., Tokarski, J., Wen, M.L., Wityak, J. & Borzilleri, R.M. (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6- (4-(2-hydroxyethyl)-piperzin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide(BMS-54825), a dual Src/Abl kinase inhibitor with potent anti-tumor activity in preclinical assays. Journal of Medicinal Chemistry, 47, 66586661.
  • Löwenberg, M., Tuynman, J., Bilderbeek, J., Gaber, T., Buttgereit, F., Van Deventer, S., Peppelenbosch, M. & Hommes, D. (2005) Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. Blood, 106, 17031710.
  • Lutsiak, M.E., Semnani, R.T., De Pascalis, R., Kashmiri, S.V., Schlom, J. & Sabzevari, H. (2005) Inhibition of CD4(+)CD25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood, 105, 28622868.
  • Martinelli, G., Soverini, S., Rosti, G. & Baccarani, M. (2005) Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia, 19, 18721879.
  • Nishikawa, H., Tsuji, T., Jäger, E., Briones, G., Ritter, G., Old, L.J., Galán, J.E., Shiku, H. & Gnjatic, S. (2008) Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood, 111, 14041412.
  • O’Hare, T., Walters, D.K., Stoffregen, E.P., Sherbenou, D.W., Heinrich, M.C., Deininger, M.W. & Druker, B.J. (2005) Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clinical Cancer Research, 11, 69876993.
  • O’Hare, T., Walter, D.K., Stoffregen, E.P., Jia, T., Manley, P.W., Mestan, J., Cowan-Jacob, S.W., Lee, F.Y., Heinrich, M.C., Deininger, M.W. & Druker, B.J. (2006) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant Imatinib-resistant Abl kinase domain mutants. Cancer Research, 65, 45004505.
  • Ottmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F., Larson, R.A., Rege-Cambrin, G., Radich, J., Hochhaus, A., Apanovitch, A.M., Gollerkeri, A. & Coutre, S. (2007) Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood, 110, 23092315.
  • Palacios, E.H. & Weiss, A. (2004) Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene, 23, 79908000.
  • Quintas-Cardama, A., Kantarjian, H., Jones, D., Nicaise, C., O’Brien, S., Giles, F., Talpaz, M. & Cortes, J. (2007) Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood, 109, 497499.
  • Sakaguchi, S. (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annual review of Immunology, 22, 531562.
  • Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of Immunology, 155, 11511164.
  • Sakaguchi, S., Toda, M., Asano, M., Itoh, M., Morse, S.S. & Sakaguchi, N. (1996) T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. Journal of Autoimmunity, 9, 211220.
  • Sakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M. & Takahashi, T. (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunological reviews, 182, 1832.
  • Sansom, D.M. & Walker, L.S. (2006) The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunological reviews, 212, 131148.
  • Schade, A.E., Schieven, G.L., Townsend, R., Jankowska, A.M., Susulic, V., Zhang, R., Szpurka, H. & Maciejewski, J.P. (2008) Dasatinib, a small molecule protein tyrosine kinase inhibitor, inhibits T cell activation and proliferation. Blood, 111, 13661377.
  • Shevach, E.M. (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nature reviews. Immunology, 2, 389400.
  • Strauss, L., Whiteside, T.L., Knights, A., Bergmann, C., Knuth, A. & Zippelius, A. (2007) Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. Journal of Immunology, 178, 320329.
  • Talpaz, M., Shah, N.P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O’Brien, S., Nicaise, C., Bleickardt, E., Blackwood-Chirchir, M.A., Iyer, V., Chen, T.T., Huang, F., Decillis, A.P. & Sawyers, C.L. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New England Journal of Medicine, 354, 25312541.
  • Tokarski, J.S., Newitt, J.A., Chang, C.Y., Cheng, J.D., Wittekind, M., Kiefer, S.E., Kish, K., Lee, F.Y., Borzillerri, R., Lombardo, L.J., Xie, D., Zhang, Y. & Klei, H.E. (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Research, 66, 57905797.
  • Walker, M.R., Kasprowicz, D.J., Gersuk, V.H., Benard, A., Van Landeghen, M., Buckner, J.H. & Ziegler, S.F. (2003) Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. Journal of Clinical Investigation, 112, 14371443.
  • Weichsel, R., Dix, C., Wooldridge, L., Clement., M., Fenton-May, A., Sewell, A.K., Zezula, J., Greiner, E., Gostick, E., Price, D.A., Einsele, H. & Seggewiss, R. (2008) Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clinical Cancer Research, 14, 24842491.
  • Weil, R. & Israel, A. (2006) Deciphering the pathway from the TCR to NF-kappaB. Cell Death and Differentiation, 13, 826833.
  • Weisberg, E., Manley, P.W., Cowan-Jacob, S.W., Hochhaus, A. & Griffin, J.D. (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nature reviews. Cancer, 7, 345356.
  • Zeiser, R., Nguyen, V.H., Beilhack, A., Buess, M., Schul, S., Baker, J., Contag, C.H. & Negrin, R.S. (2006) Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood, 108, 390399.